Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NervGen Pharma Corp. - Common stock (NQ:NGEN)

1.935 +0.015 (+0.78%)
Streaming Delayed Price Updated: 3:40 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NervGen Pharma Corp. - Common stock

News headline image
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen to Host Inaugural R&D Day on September 30, 2026
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Announces Proposed Public Offering of Securities
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Participate at Upcoming Investor Conferences
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
From NervGen Pharma Corp.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.